Holen Sie sich die Stockscreener-App
3.01
1.63%
-0.05
Handel nachbörslich:
3.06
0.05
+1.66%
Schlusskurs vom Vortag:
$3.06
Offen:
$3.06
24-Stunden-Volumen:
44,073
Relative Volume:
0.35
Marktkapitalisierung:
$96.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.48M
KGV:
-7.7179
EPS:
-0.39
Netto-Cashflow:
$-7.93M
1W Leistung:
-6.52%
1M Leistung:
-6.81%
6M Leistung:
+3.79%
1J Leistung:
-11.21%
1-Tages-Spanne:
$3.01
$3.1431
1-Wochen-Bereich:
$3.01
$3.36
52-Wochen-Spanne:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Vergleichen Sie ANIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.01 | 98.57M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences CEO Kumar buys $15,800 in stock - Investing.com Australia
Anixa Biosciences stock rises after securing Canadian patent allowance By Investing.com - Investing.com South Africa
Anixa Biosciences stock rises after securing Canadian patent allowance - Investing.com Australia
Anixa Biosciences receives Canadian patent allowance for breast cancer vaccine - Investing.com Australia
First-Ever Breast Cancer Prevention Vaccine Technology Expands Global Patent Protection in Canada - Stock Titan
How Anixa Biosciences Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it
Anixa Biosciences Inc. Earnings Report Breakdown: What Investors Should KnowEntry Plan for Oversold Reversal Stocks Released - metal.it
Should I hold or sell Anixa Biosciences Inc. stock in 2025Powerful market insights - jammulinksnews.com
What are the technical indicators suggesting about Anixa Biosciences Inc.Earnings Report Alerts For Every Investor - jammulinksnews.com
How does Anixa Biosciences Inc. compare to its industry peersMaximize your returns with expert insights - jammulinksnews.com
How many analysts rate Anixa Biosciences Inc. as a “Buy”Build wealth steadily with expert advice - jammulinksnews.com
What are analysts’ price targets for Anixa Biosciences Inc. in the next 12 monthsExplosive wealth accumulation - jammulinksnews.com
How strong is Anixa Biosciences Inc. company’s balance sheetBuild wealth with reliable stock picks - jammulinksnews.com
How Efficient Is Anixa Biosciences Inc. at Controlling Operating CostsFree Stock Movement Tracking - metal.it
What are the latest earnings results for Anixa Biosciences Inc.Achieve fast wealth growth with smart picks - jammulinksnews.com
Why is Anixa Biosciences Inc. stock attracting strong analyst attentionGrow your portfolio with growth-oriented stocks - jammulinksnews.com
What is the dividend policy of Anixa Biosciences Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
How volatile is Anixa Biosciences Inc. stock compared to the marketConsistent wealth multiplication - jammulinksnews.com
When is Anixa Biosciences Inc. stock expected to show significant growthFree Expert Stock Watchlist - jammulinksnews.com
Why Anixa Biosciences Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - metal.it
Is Anixa Biosciences Inc. stock overvalued or undervaluedTremendous return rates - jammulinksnews.com
What analysts say about Anixa Biosciences Inc. stockExplosive capital gains - PrintWeekIndia
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Anixa Biosciences Inc. a good long term investmentSuperior risk-adjusted returns - PrintWeekIndia
What institutions are buying Anixa Biosciences Inc. stock nowBreakthrough profits - jammulinksnews.com
Anixa Biosciences receives new patent for breast cancer vaccine technology By Investing.com - Investing.com Nigeria
Anixa Biosciences receives new patent for breast cancer vaccine technology - Investing.com
Revolutionary Breast Cancer Prevention Vaccine Secures Patent Protection Until 2040s$Billion Market Potential - Stock Titan
What drives Anixa Biosciences Inc. stock priceBreakthrough capital growth - Autocar Professional
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anixa Biosciences Inc-Aktie (ANIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):